NASDAQ : CHRS
Coherus Oncology, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.8301 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 128.25M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 117.45M |
| Enterprise Value | 66.32M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 154.50M |
| Shares Outstanding | 154.50M |
| Shares Change (YoY) | +14.13% |
| Shares Change (QoQ) | +13.50% |
| Owned by Insiders (%) | 12.21% |
| Owned by Institutions (%) | 42.60% |
| Float | 135.60M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.52 |
| Forward PS | 1.60 |
| PB Ratio | 2.11 |
| P/TBV Ratio | 8.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.77 |
| Quick Ratio | 1.58 |
| Debt / Equity | 0.89 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.95 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -178.39% |
| Return on Assets (ROA) | -30.52% |
| Return on Invested Capital (ROIC) | -1,586.11% |
| Return on Capital Employed (ROCE) | -133.13% |
| Weighted Average Cost of Capital (WACC) | 10.74% |
| Revenue Per Employee | $353,722 |
| Profits Per Employee | -$917,583 |
| Employee Count | 144 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 3.11 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -54.75% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.53 |
| Relative Strength Index (RSI) | 31.42 |
| Average Volume (20 Days) | 1,661,605 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 12.45M |
| Short Previous Month | 23.34M |
| Short % of Shares Out | 8.06% |
| Short % of Float | 9.18% |
| Short Ratio (days to cover) | 7.31 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 50.94M |
| Gross Profit | 35.12M |
| Operating Income | -154.00M |
| Pretax Income | -161.15M |
| Net Income | -132.13M |
| EBITDA | -150.39M |
| EBIT | -154.00M |
| Loss Per Share | -$1.00 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 105.31M |
| Total Debt | 54.18M |
| Net Cash | 51.13M |
| Net Cash Per Share | $0.33 |
| Equity (Book Value) | 60.84M |
| Book Value Per Share | 0.39 |
| Working Capital | 58.28M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -186.03M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 3.61M |
| Net Borrowing | -121,000 |
| Free Cash Flow | -186.03M |
| FCF Per Share | -$1.20 |
Margins
| Measure | Value |
|---|
| Gross Margin | 68.96% |
| Operating Margin | -302.33% |
| Pretax Margin | -316.37% |
| Profit Margin | -259.41% |
| EBITDA Margin | -295.25% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -14.13% |
| Shareholder Yield | -14.13% |
| Earnings Yield | -131.69% |
| FCF Yield | -145.05% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.75 |
| Price Target Difference | 919.47% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 58.46% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -11.68 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |